News | February 23, 2022
Complement Therapeutics raises €5 million seed financing
Appoints Dr Rafiq Hasan as CEO
Appoints Dr Rafiq Hasan as CEO
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
9T Labs provides a cost-competitive solution for manufacturing that will allow structural CFRP parts to replace metals at a much faster rate in demanding applications in many sectors such as aerospace, automotive and healthcare
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The brand has added a range of exciting new products especially formulated for oily skin.
Subscribe To Our Newsletter & Stay Updated
